Thursday

Advances in MDS Biology

Innate immune response dysfunction is now recognized as a driving force in MDS pathogenesis. Drs. List and Garcia-Manero discuss implications for diagnosis, monitoring, and future therapies.

Read More

New AML Therapies: For Whom and When?

Recent approvals of several novel therapeutic options, including the first targeted therapies, have dramatically changed treatment algorithms for AML. Drs. Stone and Erba consider the impact of new AML agents on treatment selection and sequencing for defined patient subsets.

Read More

A Glimpse at the Future of AML

Decades of research into the biology of AML are beginning to pay off – with more clinical advances in the wings. Drs. Stone and Ravandi discuss their expectations for near-term developments in AML.

Read More